Explore the latest news from Khondrion and its team.
NIJMEGEN, the Netherlands – 11 September 2024: Khondrion, a clinical stage biopharmaceutical company discovering and developing therapies targeting...
Khondrion announces grant of patents in the US and Europe for its lead candidate sonlicromanol, covering the anti-inflammatory effect on mPGES-1...
Khondrion has joined a recently established consortium of universities and industry partners to train international PhD students whose research is...
Sonlicromanol for MELAS spectrum disorders – a rare, progressive primary mitochondrial disease – to move into a Phase III registrational study...
NIJMEGEN, the Netherlands – 25 October 2022: Khondrion, a clinical-stage biopharmaceutical company discovering and developing therapies targeting...
NIJMEGEN, the Netherlands – 14 September 2022: Khondrion, a clinical-stage biopharmaceutical company discovering and developing therapies targeting...
Jan Smeitink: Serving the Mitochondrial Medicine Mission Embarking on the journey of biopharmaceutical innovation demands more than just...
Khondrion to participate in the 16th Annual Dutch Inborn Error Meeting and the United Mitochondrial Disease Foundation (UMDF) Bench to Bedside...
2022 – A Year in Review As 2022 draws to a close, Khondrion’s CEO Jan Smeitink reflects on the significant progress achieved by Khondrion in its...
How did you first become involved with the mitochondrial disease community and MitoCanada? I joined MitoCanada at a very exciting time, two months...
How did you first become involved with the mitochondrial disease community and what led you to the Mito Foundation? I first learnt of mitochondrial...
Tell us about your career before joining KhondrionI started my career as a physician in the Dutch Navy, 22 years ago, following the...
